US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nuo Therapeutics, Inc.

1.35

+0.10008.00%

Volume:12.80K

Turnover:15.88K

Market Cap:64.90M

PE:-25.42

High:1.35

Open:1.27

Low:1.13

Close:1.25

52wk High:3.23

52wk Low:0.9359

Shares:48.08M

Float Shares:22.86M

Volume Ratio:1.57

T/O Rate:0.06%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0531

EPS(LYR):-0.0293

ROE:-1032.50%

ROA:-103.65%

PB:-67.85

PE(LYR):-46.15

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Press Release: Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update

Nuo Therapeutics Q1 net loss narrows to $618,000; revenue more than doubles to $1.3 million

Roth MKM Reaffirms Their Buy Rating on Nuo Therapeutics (AURX)

Nuo Therapeutics FY25 net loss widens to $2.5 million; revenue climbs to $3.3 million

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/AURX"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"AURX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AURX\",,,,,undefined,":{"symbol":"AURX","market":"US","secType":"STK","nameCN":"Nuo Therapeutics, Inc.","latestPrice":1.35,"timestamp":1778788800000,"preClose":1.25,"halted":0,"volume":12800,"delay":15,"changeRate":0.08000000000000007,"floatShares":22864200,"shares":48077700,"eps":-0.053098,"marketStatus":"Not Yet Opened","change":0.1,"latestTime":"05-14 16:00:00 EDT Delay","open":1.27,"high":1.35,"low":1.13,"amount":15875.650000000001,"amplitude":0.176,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.053098,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1778832000000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"OTCQB","adjPreClose":1.25,"volumeRatio":1.573216},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"AURX\",,,,,undefined,":{"symbol":"AURX","floatShares":22864200,"roa":"-103.65%","roe":"-1032.50%","lyrEps":-0.029253,"volumeRatio":1.573216,"shares":48077700,"dividePrice":0,"high":1.35,"amplitude":0.176,"preClose":1.25,"low":1.13,"week52Low":0.9359,"pbRate":"-67.85","psRate":"19.59","week52High":3.23,"institutionHeld":0,"latestPrice":1.35,"eps":-0.053098,"divideRate":0,"volume":12800,"delay":15,"ttmEps":-0.053098,"open":1.27,"prevYearClose":1.97,"prevWeekClose":1.256,"prevMonthClose":1.238,"prevQuarterClose":1.45,"fiveDayClose":1.28,"twentyDayClose":1.5,"sixtyDayClose":1.6},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/AURX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-11-12","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-08-12","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723435200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2024-05-15","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715745600000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2024-04-19","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1713499200000,"reportTimeType":"post","actualEps":null},{"market":"US","date":"2023-11-20","symbol":"AURX","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1700456400000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"AURX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"AURX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":1,"updateTime":1765857600000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"AURX\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2635721360","title":"Press Release: Nuo Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2635721360","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635721360?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:24","pubTimestamp":1778793840,"startTime":"0","endTime":"0","summary":"HOUSTON, May 14, 2026  -- Nuo Therapeutics, Inc.  , a commercial-stage medical device company focused on developing and marketing regenerative therapies for chronic wound care, announced financial results for the first quarter ended March 31, 2026 and provided an operational and business update.-- Total revenues of approximately $1.3 million (including approximately. $1,224,000 of product revenues) increased 169% over the 2025 first. -- Aurix branded product revenues were up over 30% sequentially versus 2025. -- Net operating loss of approximately $446,000 compared to 2025's first. \"However, we believe we are very attractively positioned for long term success with potential for strong and attractive growth well into the future,\" concluded Jorden. \"With this financial results release, we are making the commitment to now regularly report on our progress beyond our periodic filings with the US Securities and Exchange Commission. We are enthusiastic about the remainder of 2026 and look for","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","AURX","LENZ","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635729697","title":"Nuo Therapeutics Q1 net loss narrows to $618,000; revenue more than doubles to $1.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2635729697","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635729697?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:02","pubTimestamp":1778792524,"startTime":"0","endTime":"0","summary":"Nuo Therapeutics posted Q1 net loss of USD 618,000, narrowing from USD 746,000 year earlier.Revenue more than doubled to about USD 1.3 million, including roughly USD 1.22 million in product revenue, up about 153% from prior-year period.Gross margin fell 10 percentage points to about 65%.Operating expenses climbed to about USD 1.3 million from about USD 1.11 million.Smith+Nephew private-label rollout contributed USD 78,000 of distribution-fee revenue; company ended March 31 with about USD 0.3 million in cash and flagged substantial doubt about its ability to continue as a going concern.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuo Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Elec","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDL90ndFK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627934422","title":"Roth MKM Reaffirms Their Buy Rating on Nuo Therapeutics (AURX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2627934422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627934422?lang=en_us&edition=fundamental","pubTime":"2026-04-15 05:15","pubTimestamp":1776201332,"startTime":"0","endTime":"0","summary":"Roth MKM analyst Kyle Bauser reiterated a Buy rating on Nuo Therapeutics today and set a price target of $3.00. According to TipRanks, Bauser is an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-reaffirms-their-buy-rating-on-nuo-therapeutics-aurx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-reaffirms-their-buy-rating-on-nuo-therapeutics-aurx-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["AURX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623324105","title":"Nuo Therapeutics FY25 net loss widens to $2.5 million; revenue climbs to $3.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2623324105","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623324105?lang=en_us&edition=fundamental","pubTime":"2026-03-31 05:45","pubTimestamp":1774907128,"startTime":"0","endTime":"0","summary":"Nuo Therapeutics posted a net loss of about $2.5 million for fiscal 2025.Revenue climbed to about $3.3 million, including $0.2 million of distribution fee revenue from Smith+Nephew.Gross margin narrowed to about 67% from about 78% a year earlier.Product revenue more than doubled to about $3.1 million, driven by an expanding Aurix customer base and initial Smith+Nephew private-label sales in the second half.Smith+Nephew distribution agreement includes minimum annual purchase commitments averaging about $0.5 million during the initial term starting October 2025; management expects related revenue to increase modestly over the next 12 months.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nuo Therapeutics Inc. published the original conte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL1V4cvD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AURX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":2,"pageCount":1,"totalSize":8,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/AURX\",params:#limit:6,delay:false,,,undefined,":[]}}